LSP closes sixth fund on $600m

The fund was launched in March 2018 with a $450m target and held a first close on €410m in November 2018. 

The vehicle is larger than its predecessor, which closed on its $280m hard-cap, surpassing its $170m target, in June 2016. 

LPS has raised $2.5bn since it started to invest in life sciences in 1988. The group has offices in Amsterdam, Munich and Boston. Alongside LSP 6, the firm is investing from its $300m Health Economics Fund, and its $200m public fund and mandates.

LSP's stand-out deals include Argenx, Crucell, Kudos, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma.

Investments
LSP 6 will invest in 15-18 predominantly European companies developing new medications and medical technologies. The fund has already made 12 investments.

Investors
LSP 6 attracted capital from a diverse investor base including pension funds, insurance companies, wealth managers, government funds and family offices. Among others, it received commitments from Bristol Myers Squibb and Otsuka Pharmaceutical.

People
Life Sciences Partners – René Kuijten (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Buyout
• Healthcare
• Life Science Partners